posted on July 10, 2016

SOM Biotech and the Anglo-Italian biotech accelerator Inorgen ( have successfully reached an agreement to co-develop drug repositioning programs focused mainly on rare diseases. Repositioning and rare diseases are two concepts widely known by both companies. By combining these concepts, costs and time needed to bring the drug onto the market is reduced. Safety risks are also lowered. The extensive network of Inorgen with academia, research institutions and biotech companies, along with the discovery tools and development activities of SOM Biotech makes a unique and promising way to accelerate new treatments from discovery to clinical stage.

In addition, SOM Biotech has also reached a co-development agreement with the Flanders Institute for Biotechnology, VIB ( Several drug repositioning programs will be carried out.